Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
reconstituted high-density lipoproteins
- Development stage
- Unknown
- Lead developer
- ABIONYX Pharma
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes
- Administration
- Topical
01
Overview
Reconstituted high-density lipoproteins (rHDL) is an investigational biologic being developed by the University of Adelaide's Vascular Research Centre and the South Australian Health and Medical Research Institute (SAHMRI) for the treatment of diabetic foot ulcers and impaired wound healing. The formulation consists of discoidal nanoparticles composed of apolipoprotein A-I (apoA-I) complexed with the phospholipid 1-palmitoyl-2-linoleoyl-phosphatidylcholine (PLPC). Administered topically, rHDL targets the scavenger receptor class B type I (SR-BI) and modulates the PDK4/pyruvate dehydrogenase complex (PDC) axis to rescue diabetes-impaired angiogenesis, reduce inflammation, and promote wound closure. It has been evaluated in a Phase 1/2 clinical trial in Australia for acute post-ray-amputation wounds in patients with diabetes.
- Other names
- rHDLreconstituted high-density lipoproteinreconstituted HDL
02
Targets
SCARB1 (Scavenger receptor class B member 1)PDK (Pyruvate dehydrogenase kinase isoform 1)
Beyond the preview
Go deeper on reconstituted high-density lipoproteins.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reconstituted high-density lipoproteins.